Download PDF
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(04): 154-160
DOI: 10.4103/sajc.sajc_181_17
Original Article : Head and Neck Cancers

Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck

Authors

  • Govind Babu

    Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka

  • Ankur Bahl

    Department of Medical Oncology, Max Hospital, New Delhi

  • G. S. Bhattacharya

    Department of Medical Oncology, Fortis Hospital, Kolkata, West Bengal

  • K. T. Bhowmik

    Department of Radiation Oncology, Safdarjung Hospital, New Delhi

  • P. S. Dattatraya

    Department of Medical Oncology, Omega Hospital, Hyderabad, Telangana

  • Nikhil Ghadyalpatil

    Department of Medical Oncology, Yashoda Hospitals, Hyderabad, Telangana

  • S. M. Karandikar

    Department of Medical Oncology, Ruby Hall Clinic, Pune, Maharashtra

  • Padmaj Kulkarni

    Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra

  • Nithya Sridharan

    Department of Medical Oncology, VS Hospital, Chennai, Tamil Nadu

  • Purvish Parikh

    Department of Precision Oncology, Asian Cancer Institute, Mumbai, Maharashtra

  • Kumar Prabhash

    Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra

  • T. Raja

    Department of Medical Oncology, Apollo Speciality Hospital, Chennai, Tamil Nadu

  • S. Rajasundaram

    Department of Surgical Oncology, Global Institute of Oncology, Chennai, Tamil Nadu

  • S. Subramanian

    Department of Medical Oncology, VS Hospital, Chennai, Tamil Nadu

  • Kaustav Talapatra

    Department of Radiation Oncology, KDA Hospital, Mumbai, Maharashtra

  • Ashok Vaid

    Department of Medical Oncology, Medanta Hospital, Gurugram, Haryana

Source of Support: Nill.
Further Information
Also available at
 PDF Download Permissions and Reprints

Abstract

We present the 2017 Oncology Gold Standard Practical Consensus Recommendation for use of monoclonal antibodies in the management of advanced squamous cell carcinoma of head neck region.

Key words

Combination therapy - guidelines - outcome - survival - targeted therapy


Publication History

Article published online:
22 December 2020

© 2017. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EE, Halthore A, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol 2017;7:246-53.
  • 2 Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v184-6.
  • 3 D'cruz A, Lin T, Anand AK, Atmakusuma D, Calaguas MJ, Chitapanarux I, et al. Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines. Oral Oncol 2013;49:872-7.
  • 4 NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancer Version 2.2017 of May 8, 2017. Available from: https://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf. [Last accessed on 2017 Jun 14].
  • 5 GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide 2012. International Agency for Research on Cancer: World Health Organization. Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_population.aspx. [Last accessed on 2016 Oct 03].
  • 6 International Agency for Research on Cancer GLOBOCAN 2008; 2010. Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_population.aspx. [Last accessed on 2014 Jan 27].
  • 7 Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol 2014;15:489-538.
  • 8 Varshitha AJ. Prevelance of oral cancer in India. J Pharmacol Sci Res 2015;7:845-8.
  • 9 Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol 2011;100:33-40.
  • 10 Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
  • 11 Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet 2010;11:21-8.
  • 12 Rodríguez MO. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010;9:343-9.
  • 13 Reddy BK, Lokesh V, Vidyasagar MS, Shenoy K, Babu KG, Shenoy A, et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol 2014;50:498-505.
  • 14 Rawat S, Ahlawat P, Kakria A, Kumar G, Rangaraju RR, Puri A, et al. Comparison between weekly cisplatin-enhanced radiotherapy and cetuximab-enhanced radiotherapy in locally advanced head and neck cancer:First retrospective study in Asian population. Asia Pac J Clin Oncol 2017;13:195-203.
  • 15 Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: Radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004;72:257-66.
  • 16 Nozawa H, Tadakuma T, Ono T, Sato M, Hiroi S, Masumoto K, et al. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 2006;97:1115-24.
  • 17 Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial. Lancet Oncol 2013;14:697-710.
  • 18 Rivera F, García-Castaño A, Vega N, Vega-Villegas ME, Gutiérrez-Sanz L. Cetuximab in metastatic or recurrent head and neck cancer: The EXTREME trial. Expert Rev Anticancer Ther 2009;9:1421-8.
  • 19 Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, et al. Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: A Randomized Clinical Trial. JAMA Oncol 2016.
  • 20 Schick U, Gujral DM, Richards TM, Harrington KJ, Nutting CM. Zalutumumab in head and neck cancer. Expert Opin Biol Ther 2012;12:119-25.
  • 21 Pembrolizumab (KEYTRUDA). US Food & Drug Administration. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm515627.htm. [Last updated on 2016 Sep 08; Last cited on 2016 Dec 12].
  • 22 Ferris RL. Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. J Clin Oncol 2016. [Suppl; Abstr 6009].
  • 23 Syed YY. Durvalumab:First global approval. Drugs 2017;77:1369-76.
  • 24 Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile. Cancer Biol Ther 2011;11:373-82.
  • 25 Merlano M, Russi E, Benasso M, Corvò R, Colantonio I, Vigna-Taglianti R, et al. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: A phase II clinical study. Ann Oncol 2011;22:712-7.
  • 26 Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940-50.
  • 27 Magrini SM, Buglione M, Corvò R, Pirtoli L, Paiar F, Ponticelli P, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: A Randomized Phase II Trial. J Clin Oncol 2016;34:427-35.
  • 28 Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072-8.
  • 29 Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1:41-8.
  • 30 Kong L, Lin Q, Hu C, Xu T, Liao X. Radiation plus concurrent minotuzumab versus CDDP in locally advances nasopharyngeal cancer: Result of a phase III randomized study. JCO 2016;34. [Suppl Abst. 6002].
  • 31 Kataria T, Gupta D, Bisht SS, Goyal S, Basu T, Srivastava A, et al. Chemoradiation in elderly patients with head and neck cancers: A single institution experience. Am J Otolaryngol 2015;36:117-21.
  • 32 Shukla P, Gupta D, Munshi A, Agarwal JP. Cetuximab and cancers of the head and neck: Tapping the circadian rhythm. Med Hypotheses 2011;77:336-8.
  • 33 Agarwal JP, Gupta T, Kalyani N, Budrukkar A, Laskar SG, Murthy V, et al. Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice? Indian J Cancer 2011;48:148-53.
  • 34 Dattatreya S, Goswami C. Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region – A open labelled single arm phase II study. Indian J Cancer 2011;48:154-7.
  • 35 Rangaraju RR, Sharma JB, Dewan AK, Anand AK, Sheh R, Jena A, et al. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: A retrospective analysis. Indian J Cancer 2012;49:1-5.
  • 36 Huilgol NG. A retrospective analysis of patients with head and neck cancer treated with radiation, hyperthermia, and cetuximab: A brief report of outcome. J Cancer Res Ther 2016;12:1164-66.
  • 37 Tiwari S, Goel V, John MC, Patnaik N, Doval DC. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study. Indian J Cancer 2016;53:487-92.
  • 38 Noronha V, Patil VM, Joshi A, Bhattacharjee A, Paul D, Dhumal S, et al. A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers. South Asian J Cancer 2017;6:11-4.
  • 39 Bhowmick KT. Results from a pilot study of nimotuzumab with concurrent CRT in patients with LASCCHN. J Clin Oncol 2010;28:1. [Abstr. 5565].
  • 40 Karandikar. Retrospective analysis of H & N cancer patients successfully treated with chemoradaition plus nimotuzumab. J Clin Oncol 2012;29:1. [Abstract e1601].
  • 41 Bhatnagar. A comparative study of Mab against EGFR (Nimotuzumab) used in combination with CRT vs. CRT alone in the treatment of LASCCHN. J Clin Oncol 2012;30:1. [Abstr. e51].
  • 42 Kumar A. To assess the possibility of combining Mab (Nimotuzumab) with concurrent CRT in patients with LASCCHN. Indian J Med Paediatr Oncol 2012. [Suppl Abstr. p1].
  • 43 Somani N. Nimotuzumab in concurrent chemoradiotherapy in patients with locally advanced head and neck cancer (LASCCHN). J Cancer Ther 2015;6:356-61.
  • 44 Bahl A. Nimotuzumab with concurrent chemoradiation in inoperable locally advanced squamous cell carcinoma of head and neck: An Indian experience. Available from: http://www.uaecancercongress.ae/pdf/UAECC2016_H&N_SP_20160919.pdf. [Last accessed on 2017 Mar 12].
  • 45 Subramanian S. Nimotuzumab in induction chemotherapy in patients with advanced head and neck cancer – Retrospective study. J Cancer Ther 2015;6:146-52.
  • 46 Talapatra K. Nimotuzumab and intensity modulated radiation therapy (IMRT) in the concurrent setting of locally advanced head and neck cancers: Early results of a prospective trial in India. Int J Radiat Oncol 2016. [Supp 2S Abstr. 96].
  • 47 Kondaveeti SS. Therapeutic effect of concurrent radiation with single agent nimotuzumab in locally advanced and recurrent HNSCC: Retrospective analysis. Int J Radiat Oncol 2014;90:561.
  • 48 Paccagnella A, Ghi MG, Floriani I. Concomitant Chemoradiation or RT/Cetuximab Versus Induction TPF Followed by Chemoradiation or RT/Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Randomized Phase III Factorial Study on Behalf of GSTTC Italian Collaborative Group. Available from: http://www.ascopubs.org/doi/abs/10.1200/jco. 2011.29.15_suppl.tps196.
  • 49 Ghi MG. Cetuximab/Radiotherapy (CET+RT) Versus Concomitant Chemoradiotherapy (cCHT+RT) with or without Induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) in Locally Advanced Head and Neck Squamous Cell Carcinoma (LASCCHN): Preliminary Results on Toxicity of a Randomized, 2×2 Factorial Phase II-III Study (NCT01086826). 2012 ASCO Annual Meeting. Available from: http://www.meetinglibrary.asco.org/content/69636?media=vm. [Last accessed on 2016 Dec].